NeuroMetrix, Inc. (NURO) just recently stated financial and company highlights for the quarter ended September 30, 2019.
The Healthcare sector business, On Saturday, Neurometrix Inc (NASDAQ: NURO) began its trading session with the price $0.31 and closed at price of $0.28 by scoring -5.12%. Day variety of the stock was $0.28 – $0.31. NURO stock traded with overall volume of 47187 shares while the average trading capacity remained 176918 shares.
The Company just recently reported structured Quell circulation under an exclusively direct-to-consumer design via the QuellRelief.com platform. The model includes available pricing to reach a more comprehensive market. The Company believes these changes could lead to improved economics by means of lowered consumer acquisition expenses, distribution channel savings, and much better retention rates.
The Q2 2019 service restructuring, combined with Quell migration from TV to digital marketing, contributed to a $1.9 M decrease in operating costs from the previous year quarter.
DPNCheck incomes in Q3 2019 were about $1.0 M in contrast with $1.1 M in Q3 2018. International earnings was down by $0.3 M.
Quell revenues incomes Q3 2019 were $0.8 M in comparison contrast $2.2 M in Q3 2018.
Loss from operations was $1.4 M in Q3 2019 in comparison with a loss of $2.7 M in Q3 2018.
As before exposed, the Company continues to check out a potential divestiture of its DPNCheck business and other planned alternatives to boost shareholder value, including the potential sale or merger of the business.
In Q3 2019 total incomes were $2.1 M, down 43% from $3.7 M in the previous year period. Operating expenditures were $2.6 M, a reduction of $1.9 M from $4.5 M in Q3 2018. Net cash use in operations was $2.2 M, a decrease from $3.3 M in Q3 2018.
DPNCheck profits in Q3 2019 were about $1.0 M in comparison with $1.1 M in Q3 2018. International revenue was down by $0.3 M.
Quell revenues profits Q3 2019 were $0.8 M in comparison contrast $2.2 M in Q3 2018. In Q3 2019 total incomes were $2.1 M, down 43% from $3.7 M in the previous year period. Operating costs were $2.6 M, a decrease of $1.9 M from $4.5 M in Q3 2018. Net cash use in operations was $2.2 M, a reduction from $3.3 M in Q3 2018.
Clarence Franklin – Healthcare
I am Clarence Franklin and I focus on breaking news stories and ensuring we (“TOP MAGAZINE WIRE”) offer timely reporting on some of the most recent stories released through market wires about “Healthcare” sector companies. I have formerly spent over 7 years as a trader in U.S. Stock Market and is now semi-stepped down.